All In Biotech

Drug Trial Radar · NCT05308472

Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and PPIX Concentrations in Participants With EPP

(AURORA) A Randomized, Double-blind, Placebo-Controlled Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and Protoporphyrin IX (PPIX) Concentrations in Participants With Erythropoietic Protoporphyria (EPP)

Last checked: Nov 19, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

75

Actual

Start

Oct 31, 2022

Primary completion

Feb 20, 2024

Study completion Aug 23, 2024

Sponsor

Lead sponsor
Disc Medicine, IncIndustry
Sponsor type
Industry
First posted
Apr 4, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, multi-center, double-blind, placebo-controlled, parallel group study of bitopertin to evaluate the safety, tolerability, efficacy, and PPIX concentration change in participants with EPP. Participants may roll over to an open label extension portion after completing the double-blind treatment period.

Conditions

  • Erythropoietic Protoporphyria

Interventions

  • DISC-1459Drug

    Oral dose level 1, once a day for 120 days

  • DISC-1459Drug

    Oral dose level 2, once a day for 120 days

  • PlaceboDrug

    Oral dose, once a day for 120 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in Whole Blood Metal-free PPIX LevelsTime frame: 121 days

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama Hospital

    Birmingham, Alabama

  • University of California San Francisco

    San Francisco, California

  • University of Miami Miller School of Medicine

    Miami, Florida

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Mount Sinai Hospital

    New York, New York

  • Atrium Health Wake Forest Baptist

    Winston-Salem, North Carolina

  • Einstein Medical Center

    Philadelphia, Pennsylvania

  • University of Texas

    Galveston, Texas

  • Fred Hutchinson Cancer Center

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.